☆ 4.8 Letter

Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis

GASTROENTEROLOGY (2017)

期刊

GASTROENTEROLOGY

卷 152, 期 4, 页码 911-912

出版社

W B SAUNDERS CO-ELSEVIER INC

DOI: 10.1053/j.gastro.2016.12.021

关键词

-

类别

Gastroenterology & Hepatology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Virology

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma

Shou-Wu Lee, Li-Shu Chen, Sheng-Shun Yang, Yi-Hsiang Huang, Teng-Yu Lee

Summary: In patients with BCLC stage B/C HCC, DAA therapy can achieve a high SVR rate, except for those with PD to prior HCC treatments. SVR is related to improvements in OS, therefore, DAA therapy should be encouraged for patients diagnosed without a short life expectancy.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma

Shogo Tanaka, Hiroji Shinkawa, Akihiro Tamori, Shigekazu Takemura, Sawako Uchida-Kobayashi, Ryosuke Amano, Kenjiro Kimura, Go Ohira, Kohei Nishio, Jun Tauchi, Masahiko Kinoshita, Norifumi Kawada, Shoji Kubo

Summary: A study examined the effects of direct-acting antiviral (DAA)-induced sustained virological response (SVR) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after liver resection. While DAA-induced SVR itself may not suppress postoperative recurrence, the study found that DAA treatment improved liver function and prolonged postoperative survival in patients.

HEPATOLOGY RESEARCH (2021)

添加到收藏夹

Article Virology

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

Naoki Kawagishi, Goki Suda, Yoshiya Yamamoto, Masaru Baba, Ken Furuya, Osamu Maehara, Shunsuke Ohnishi, Sonoe Yoshida, Qingjie Fu, Zijian Yang, Shunichi Hosoda, Yoshimasa Tokuchi, Takashi Kitagataya, Masatsugu Ohara, Kazuharu Suzuki, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto

Summary: This study evaluated the predictive value of serum Ang2 levels for the occurrence and recurrence of HCC after treatment with direct-acting antiviral (DAA) medication in HCV-infected patients. The results showed that age ≥75 years and baseline Ang2 levels ≥464 pg/mL were significantly associated with the occurrence of HCC after DAA therapy. The combination of age and baseline Ang2 levels could distinguish between high and low-risk groups for HCC after DAA therapy. Furthermore, baseline Ang2 levels ≥402 pg/mL were significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs. In conclusion, serum Ang2 levels can predict the occurrence and recurrence of HCC after successful eradication of HCV by DAAs.

VIRUSES-BASEL (2023)

添加到收藏夹

Review Medicine, General & Internal

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate

Ahmed Kamal, Ahmed Elsheaita, Mahmoud Abdelnabi

Summary: Since the introduction of DAAs in hepatitis C virus treatment, the SVR rate has significantly increased. There is a debate regarding the impact of DAAs on HCC development, and current evidence does not confirm or refute an association between DAA therapy and de novo HCC occurrence or recurrence. More research is needed to determine if such an association exists.

WORLD JOURNAL OF CLINICAL CASES (2022)

添加到收藏夹

Review Medicine, General & Internal

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection

Pil Soo Sung, Eui-Cheol Shin

Summary: The use of DAAs in treating chronic HCV infection can lead to rapid changes in the phenotypes of NK and MAIT cells, potentially reducing their cytotoxicity against cancer cells. Additionally, DAAs treatment does not normalize the increased frequencies of regulatory T cells, which may contribute to local immunosuppression and hinder cancer cell clearance.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer

Ryoko Kuromatsu, Tatsuya Ide, Shusuke Okamura, Yu Noda, Naoki Kamachi, Masahito Nakano, Tomotake Shirono, Shigeo Shimose, Hideki Iwamoto, Reiichiro Kuwahara, Teruko Arinaga-Hino, Takashi Niizeki, Yuki Zaizen, Hiroshi Takaki, Miki Shirachi, Hironori Koga, Takuji Torimura

Summary: In patients with hepatitis C virus-related liver disease, the use of direct-acting antivirals (DAAs) after curative hepatocellular carcinoma treatment can effectively suppress its recurrence.

CANCERS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Masahide Oshita, Hideki Hagiwara, Mitsuru Sakakibara, Shinji Tamura, Naoki Hiramatsu, Masami Inada, Sadaharu Iio, Toshifumi Ito, Takayuki Yakushijin, Yoshinori Doi, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara

Summary: The study aimed to investigate the clinical course in HCV-positive patients with decompensated liver cirrhosis after DAAs treatment. Approximately one-fourth of the patients received DAA treatment, but more than 40% lost the opportunity for it. Overall survival was significantly shorter and the HCC occurrence and hospitalization rates were higher in C-P C patients than in C-P B patients.

HEPATOLOGY RESEARCH (2021)

添加到收藏夹

Article Oncology

Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation

Taisuke Imamura, Yukiyasu Okamura, Keiichi Ohshima, Katsuhiko Uesaka, Teiichi Sugiura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi, Shimpei Otsuka, Sumiko Ohnami, Takeshi Nagashima, Keiichi Hatakeyama, Yuko Kakuda, Takashi Sugino, Kenichi Urakami, Yasuto Akiyama, Ken Yamaguchi

Summary: This study compared the genomic characteristics of hepatocellular carcinoma (HCC) in patients with hepatitis C virus infection who achieved sustained virological response (SVR) or not after surgery using gene expression profiling and whole-exome sequencing. The study found significant differences in mutation rates of several driver genes between HCCs of SVR patients and non-SVR patients, as well as between HCCs of SVR patients treated with direct-acting antivirals (DAA) and interferon (IFN).

CANCER MEDICINE (2022)

添加到收藏夹

Article Oncology

Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma

Mohamed Saleh Ismail, Islam Mohamed, Efstathia Polychronopoulou, John A. Goss, Yong-Fang Kuo, Fasiha Kanwal, Prasun K. Jalal

Summary: Liver transplant recipients in the IFN-free DAA treatment era had significantly higher rates of complete tumor necrosis in the explants. Other HCC tumor characteristics were similar between the two eras. Post-LT graft failure rates at 1 and 3 years significantly decreased in the IFN-free DAA treatment era among patients with HCV and HCC, although patient mortality rates were not significantly different.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents

Alessia Ciancio, Davide G. Ribaldone, Anna Dotta, Chiara Giordanino, Marco Sacco, Sharmila Fagoonee, Rinaldo Pellicano, Giorgio M. Saracco

Summary: The study found that clearance of HCV by DAAs led to long-term improvement in glycometabolic control in diabetic patients, but diabetes still had a detrimental effect on the liver in cirrhotic patients.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Immunology

Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus

Viola Guardigni, Alice Toschi, Lorenzo Badia, Elena Rosselli Del Turco, Eleonora Salsi, Francesco Cristini, Laura Sighinolfi, Gabriele Fabbri, Marco Massari, Gianluca Cuomo, Pierluigi Viale, Gabriella Verucchi

Summary: This study aimed to determine the rate of hepatocellular carcinoma (HCC) occurrence after direct-acting antiviral (DAA) treatment in cirrhotic HIV/HCV-coinfected patients. Factors associated with HCC included higher Child--Pugh Turcotte (CPT) score, HCV genotype 3, previous HCC history, and higher CD4(+) cell count. Antiretroviral therapy (ART) was found to have a protective role in reducing the risk for HCC development.

AIDS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Treating paediatric hepatitis C in the era of direct-acting antiviral agents

Saleh A. Alqahtani, Massimo G. Colombo

Summary: The prevalence and burden of hepatitis C virus (HCV) in children are poorly understood. Vertical transmission and injection drug use are the main modes of infection. Early diagnosis and treatment are crucial in preventing HCV-induced severe liver disease. Direct-acting antiviral drugs have shown to be as safe and effective in young HCV patients as in adults.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C

Kuo-Tung Tang, Ching-Chun Lin, Yi-Hsing Chen, Tsai-Ling Liao, Der-Yuan Chen, Sheng-Shun Yang, Chia-Chang Chen

Summary: This study investigated the impact of direct-acting antiviral drugs (DAA) therapy on fibromyalgia (FM) symptoms in patients with chronic hepatitis C (CHC). The results showed that CHC patients were more likely to develop FM and implementation of DAA therapy might improve FM symptoms in these patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria

Hironori Ochi, Atsushi Hiraoka, Masashi Hirooka, Yohei Koizumi, Michiko Amano, Nobuaki Azemoto, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Toshie Mashiba, Tomoyuki Yokota, Masanori Abe, Kojiro Michitaka, Yoichi Hiasa, Kouji Joko

Summary: DAAs treatment after HCC can prevent hepatic functional reserve deterioration and significantly improve both recurrence and survival rates. This study showed that in patients receiving DAAs treatment, the 48-month survival rate was 91.0% and the recurrence rate was 36.7%, both significantly better than in patients not receiving DAAs treatment.

JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Young-Hwan Ahn, Heirim Lee, Do Young Kim, Hye Won Lee, Su Jong Yu, Young Youn Cho, Jeong Won Jang, Byoung Kuk Jang, Chang Wook Kim, Hee Yeon Kim, Hana Park, Hyo Jung Cho, Bumhee Park, Soon Sun Kim, Jae Youn Cheong

Summary: This study evaluated the efficacy of DAA therapy in Korean patients with HCV-related HCC and found a correlation between short last HCC treatment duration and HCC recurrence. The results suggest that the last HCC treatment duration is an important predictor of HCC recurrence after DAA therapy.

GUT AND LIVER (2021)

添加到收藏夹

Article Oncology

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience

Maen Abdelrahim, David Victor, Abdullah Esmail, Sudha Kodali, Edward A. Graviss, Duc T. Nguyen, Linda W. Moore, Ashish Saharia, Robert McMillan, Joy N. Fong, Ahmed Uosef, Mahmoud Elshawwaf, Kirk Heyne, Rafik M. Ghobrial

Summary: This study compared the outcomes of HCC patients treated with TACE plus sorafenib versus TACE monotherapy and found that the combination therapy was generally well-tolerated and associated with improved overall survival. However, further multicenter and prospective randomized controlled trials are needed to confirm these findings.

CANCERS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Antibiotic Prophylaxis for Upper Gastrointestinal Bleed in Liver Cirrhosis; Less May Be More

Yousaf B. Hadi, Raja S. Khan, Dhairya A. Lakhani, Ali Y. Khan, Rida U. Jannat, Adnan Aman Khan, Syeda Fatima Naqvi, George Obeng, Justin T. Kupec, Ashwani K. Singal

Summary: This study aimed to investigate the effect of shorter antibiotic duration on patient outcomes in patients with cirrhosis and upper gastrointestinal bleeding. A retrospective study of 980 cirrhosis patients found that a short course of antibiotics (around 3 days) for prophylaxis is safe and sufficient in the absence of active infection.

DIGESTIVE DISEASES AND SCIENCES (2023)

添加到收藏夹

Article Oncology

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience

Maen Abdelrahim, Abdullah Esmail, Jiaqiong Xu, Godsfavour Umoru, Hadeel Al-Rawi, Ashish Saharia, Ala Abudayyeh, David Victor, Robert McMillan, Sudha Kodali, Rafik M. Ghobrial

Summary: This study investigates the potential efficacy of Gemcitabine plus Cisplatin as a neo-adjuvant treatment for cholangiocarcinoma patients prior to liver transplantation. The results suggest improved overall survival outcomes with Gemcitabine plus Cisplatin compared to non-Gemcitabine/Cisplatin regimens in these patients.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations

Pradeep Yarra, Winston Dunn, Zobair Younossi, Yong-Fang Kuo, Ashwani K. Singal

Summary: This study found that previous RYGB in patients with AC is associated with increased likelihood of concomitant AH, hepatic encephalopathy, and infection, but similar in-hospital mortality.

DIGESTIVE DISEASES AND SCIENCES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US

Ashwani K. Singal, Yong-Fang Kuo, K. Rajender Reddy, Ramon Bataller, Paul Kwo

Summary: The study found that in 2019, there were 27,180 hospitalisations caused by Hepatorenal syndrome (HRS), requiring an estimated $4.2 billion USD in healthcare expenditures. Despite a decrease in in-hospital mortality over time, HRS remains a significant cause of death in patients hospitalized with cirrhosis.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Letter Gastroenterology & Hepatology

Possible link between higher ammonia levels, non-alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic disease?

Mohamed A. Elfeki, Ashwani K. Singal

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Editorial: The US burden of HRS--AKI--Putting numbers to the problem: Authors' reply

Nipun Verma, Ashwani K. Singal

Summary: This article is linked to the papers by Singal et al. To read these papers, visit...

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Editorial: mitochondrial respiratory chain activity-a potential link with disease severity and treatment response in alcoholic hepatitis

Ashwani K. K. Singal

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Nomogram model for hospitalized patients in the ICU for alcohol-related cirrhosis: A step closer to the continuing search for an ideal prognostic model

Anand V. Kulkarni, Ashwani K. Singal

DIGESTIVE AND LIVER DISEASE (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future

Chencheng Xie, Ashwani K. Singal

HEPATOLOGY INTERNATIONAL (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Integrated Multidisciplinary Management of Alcohol-Associated Liver Disease

Malia Holbeck, Hannah Statz DeVries, Ashwani K. Singal

Summary: Alcohol-associated liver disease (ALD) is a common liver disease and a reason for liver transplantation (LT). Patients with ALD often have alcohol use disorder (AUD) and psychiatric comorbidities. Early identification of ALD and treatment of AUD can prevent progression to advanced stages of the disease. However, there are barriers to screening and treatment for AUD in ALD patients. This review discusses the multidisciplinary care model for managing the dual pathology of ALD and AUD, with a focus on the roles of hepatologists, psychiatrists, addiction counselors, and social workers.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Waitlist and post-transplant outcomes among candidates listed for liver transplant: Liver alone versus simultaneous liver kidney listings

Ashwani K. Singal, Yong-Fang Kuo

Summary: This study compared the waitlist and post-transplant outcomes of liver transplantation alone (LTA) and simultaneous liver kidney (SLK) listings. It found that SLK patients had lower mortality on the waitlist and higher survival rates after transplantation. Therefore, the kidney function of patients should be taken into consideration when choosing the transplantation method.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Therapeutic targets in alcohol-associated liver disease: progress and challenges

Ayooluwatomiwa Deborah Adekunle, Adeyinka Adejumo, Ashwani K. K. Singal

Summary: Alcohol-associated liver disease (ALD) is a complex and rapidly increasing disease without approved therapeutic targets. Challenges in study designs and clinical trials need to be overcome to drive drug development in this field. ALD management should focus on achieving and maintaining alcohol abstinence, while early liver transplantation protocols and noninvasive biomarkers require improvement. Integrated multidisciplinary care models are urgently needed to improve long-term outcomes for ALD patients with alcohol use disorder and liver disease.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin

Ashwani K. Singal, Lorenzo Leggio, Andrea DiMartini

Summary: Alcohol-associated liver disease (ALD) is a leading cause for liver transplantation (LT) globally, particularly during the COVID-19 pandemic and among young individuals. Alcohol use disorder (AUD) is prevalent in the majority of ALD patients, and early liver transplantation (eLT) has emerged as a potential treatment for selected patients with alcohol-associated hepatitis. However, the challenge lies in addressing AUD treatment, which requires an integrated multidisciplinary care approach.

LIVER TRANSPLANTATION (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry

Zobair M. Younossi, Yusuf Yilmaz, Mohamed El-Kassas, Ajay Duseja, Saeed Hamid, Gamal Esmat, Nahum Mendez-Sanchez, Wah Kheong Chan, Ashwani K. Singal, Brian Lam, Sean Felix, Elena Younossi, Manisha Verma, Jillian K. Price, Fatema Nader, Issah Younossi, Andrei Racila, Maria Stepanova

Summary: Patients with chronic liver disease may experience a significant burden from COVID-19 infection and the pandemic. A survey found that 11.3% of patients reported an impact on their liver disease, with 73% experiencing delays in follow-up care. Furthermore, 81% of patients with a history of COVID-19 and 69% without a history experienced worsening in at least one area.

HEPATOLOGY COMMUNICATIONS (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.